Velan Capital Investment Management LP Acquires Shares of 181,367 Replimune Group, Inc. (NASDAQ:REPL)

Velan Capital Investment Management LP acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 181,367 shares of the company's stock, valued at approximately $2,196,000. Replimune Group accounts for about 1.9% of Velan Capital Investment Management LP's holdings, making the stock its 12th biggest position. Velan Capital Investment Management LP owned 0.27% of Replimune Group as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sterling Capital Management LLC increased its stake in shares of Replimune Group by 364.5% in the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its stake in Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Replimune Group in the 4th quarter valued at about $117,000. Finally, Quantinno Capital Management LP acquired a new stake in Replimune Group in the 4th quarter worth about $127,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Price Performance

REPL stock opened at $7.85 on Monday. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a market capitalization of $604.57 million, a PE ratio of -2.56 and a beta of 0.68. The business has a 50 day simple moving average of $8.95 and a 200-day simple moving average of $11.32.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on REPL shares. JPMorgan Chase & Co. increased their target price on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.